Lafiya-Malaria

Za a magance cutar Malaria har abada

Zazzabin cizon sauro na kashe mutane akalla dubu 400 a kowacce sekara a sassan duniya
Zazzabin cizon sauro na kashe mutane akalla dubu 400 a kowacce sekara a sassan duniya Olympia DE MAISMONT AFP

Kamfanin BioNTech na Jamus da ya yi hadin guiwa da takwaransa na Amurka wato Pfizer wajen samar da rigakafin korona, ya ce, nan kusa zai fara gwajin rigakafin cutar Malaria ta hanyar amfani da fasahar mRNA.

Talla

Muddin wannan gwajin na BioNTech ya samu nasara, hakan zai kasance wani gagarumin tsani na yaki da cutar zazzabin cizon-sauro ko kuma Malaria wadda ke lakume rayukan mutane fiye da dubu 400 a duk shekara, akasari kananan yara a nahiyar Afrika.

Shugaban kamfanin na BioNTech Ugur Sahin ya ce,  za su yi duk mai yiwuwa domin kera rigakafin mai inganci wanda zai kawar da Malaria, ya kuma rage yawan mace-mace.

Kamfanin ya bayyana cewa, zai gudanar da jerin gwaje-gwajensa kan wasu kebantattun halittu, yayin da za a fara gwajin a dakin kimiya nan da karshen shekarar 2022.

Tuni Hukumar Lafiya ta Duniya WHO da Cibiyar Yaki da Cutuka masu Yaduwa ta Afrika da kuma Kungiyar Tarayyar Turai suka yi lale marhabin da wannan aikin.

BioNTech ya ce, yana duba yiwuwar kafa cibiyar gwajin mRNA a Afrika don kera rigakafin na Malaria tare da rarraba shi kai tsaye a nahiyar.

Masana kimiya sun yi amannan cewa, rigakafin mRNA zai iya taka rawa wajen magance cutuka iri-iri.

Shi dai mRNA na zaburar da garkuwar jikin dan Adam wajen yakar  kwayoyin cutar da suka daskare a jikin mutun.

LabaranSamun Labaran RFI, Hirarraki, Rubattattuun Labarai, Labarai game da wani, shirye-shirye.